BE900652A - 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2, et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs. - Google Patents

2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2, et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs.

Info

Publication number
BE900652A
BE900652A BE0/213705A BE213705A BE900652A BE 900652 A BE900652 A BE 900652A BE 0/213705 A BE0/213705 A BE 0/213705A BE 213705 A BE213705 A BE 213705A BE 900652 A BE900652 A BE 900652A
Authority
BE
Belgium
Prior art keywords
histamine
disubstituees
pyrimidones
compounds
pharmaceutical compositions
Prior art date
Application number
BE0/213705A
Other languages
English (en)
Inventor
A A Algieri
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of BE900652A publication Critical patent/BE900652A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Des antagoniste récepteurs d'histamine H2, qui sont des inhibiteurs efficaces de la secrétion d'acide gastrique chez les animaux, incluant l'homme et sont utiles dans le traitement d'ulcère peptique et d'autres états pathologiques provoqués ou exacerbés par l'acide gastrique, répondent à la formule générale (I) ou un sel d'addition d'acide pharmaceutiquement acceptable non toxique d'un tel composé. L'administration se fait oralement, parentéralement ou par suppositoire.
BE0/213705A 1983-09-21 1984-09-21 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2, et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs. BE900652A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/534,426 US4772704A (en) 1983-09-21 1983-09-21 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity

Publications (1)

Publication Number Publication Date
BE900652A true BE900652A (fr) 1985-03-21

Family

ID=24129972

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213705A BE900652A (fr) 1983-09-21 1984-09-21 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2, et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs.

Country Status (36)

Country Link
US (1) US4772704A (fr)
JP (1) JPH0643310B2 (fr)
KR (1) KR900001198B1 (fr)
AR (2) AR242385A1 (fr)
AT (1) AT387965B (fr)
AU (1) AU583479B2 (fr)
BE (1) BE900652A (fr)
CA (1) CA1260463A (fr)
CH (1) CH665840A5 (fr)
CS (1) CS249147B2 (fr)
CY (1) CY1561A (fr)
DD (1) DD226881A5 (fr)
DE (1) DE3434578A1 (fr)
DK (1) DK162987C (fr)
ES (4) ES8607253A1 (fr)
FI (1) FI83868C (fr)
FR (1) FR2552082B1 (fr)
GB (1) GB2146994B (fr)
GR (1) GR80439B (fr)
HK (1) HK73790A (fr)
HU (1) HU193227B (fr)
IE (1) IE58083B1 (fr)
IL (1) IL72990A (fr)
IT (1) IT1176739B (fr)
LU (1) LU85550A1 (fr)
NL (1) NL8402898A (fr)
NO (1) NO161561C (fr)
NZ (1) NZ209572A (fr)
OA (1) OA07820A (fr)
PT (1) PT79256B (fr)
SE (1) SE463209B (fr)
SG (1) SG60890G (fr)
YU (1) YU45205B (fr)
ZA (1) ZA847345B (fr)
ZM (1) ZM4984A1 (fr)
ZW (1) ZW16084A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質ｔａｎ―１０５７，その製造法および用途
EP4196793A1 (fr) 2020-08-11 2023-06-21 Université de Strasbourg Bloqueurs de h2 ciblant des macrophages du foie pour la prévention et le traitement d'une maladie du foie et du cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151188B (fr) * 1978-02-13 1983-03-05 Smith Kline French Lab
ES477520A1 (es) * 1978-02-25 1979-06-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevas penicilinas.
AU527202B2 (en) * 1978-04-11 1983-02-24 Smith Kline & French Laboratories Limited 2-aminopyrimidones
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4521418A (en) * 1979-02-21 1985-06-04 Smith Kline & French Laboratories Limited Guanidinothiazolyl derivatives
AU531142B2 (en) * 1979-04-04 1983-08-11 Smith Kline & French Laboratories Limited 2 amino- pyimindones
CA1140129A (fr) * 1979-08-21 1983-01-25 Ronald J. King Derives de la 4-pyrimidone
ZW21281A1 (en) * 1980-10-01 1981-11-18 Smith Kline French Lab Amine derivatives
US4352933A (en) * 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
NZ202797A (en) * 1981-12-28 1985-08-30 Lilly Co Eli Pyrimidine derivatives and pharmaceutical compositions
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
GB8320505D0 (en) * 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
CA1275097A (fr) * 1984-10-02 1990-10-09 Fujio Nohara Derives de pyridyloxy

Also Published As

Publication number Publication date
CA1260463A (fr) 1989-09-26
CH665840A5 (de) 1988-06-15
ZW16084A1 (en) 1985-01-16
KR850002259A (ko) 1985-05-10
GB2146994B (en) 1987-09-03
DE3434578A1 (de) 1985-04-11
OA07820A (fr) 1986-11-20
SE463209B (sv) 1990-10-22
SG60890G (en) 1990-09-07
JPS6087271A (ja) 1985-05-16
GR80439B (en) 1985-01-22
JPH0643310B2 (ja) 1994-06-08
FI83868B (fi) 1991-05-31
PT79256B (en) 1986-11-20
KR900001198B1 (ko) 1990-02-28
AR242385A1 (es) 1993-03-31
ATA300984A (de) 1988-09-15
FI843643A0 (fi) 1984-09-18
AU583479B2 (en) 1989-05-04
DK450484A (da) 1985-03-22
IE842406L (en) 1985-03-21
ES8607253A1 (es) 1986-05-16
FI843643L (fi) 1985-03-22
ES8704155A1 (es) 1987-03-16
SE8404729D0 (sv) 1984-09-20
NO161561B (no) 1989-05-22
IL72990A (en) 1990-07-12
NZ209572A (en) 1988-05-30
ES536054A0 (es) 1986-05-16
ZM4984A1 (en) 1985-05-21
ES551500A0 (es) 1987-03-16
NO161561C (no) 1989-08-30
YU161384A (en) 1987-12-31
US4772704A (en) 1988-09-20
YU45205B (en) 1992-05-28
ES551501A0 (es) 1987-01-16
CY1561A (en) 1991-03-22
DD226881A5 (de) 1985-09-04
NL8402898A (nl) 1985-04-16
DK450484D0 (da) 1984-09-20
IT8422744A1 (it) 1986-03-20
ES544213A0 (es) 1987-04-01
DK162987C (da) 1992-06-01
AU3335184A (en) 1985-03-28
FR2552082A1 (fr) 1985-03-22
FR2552082B1 (fr) 1987-02-20
FI83868C (fi) 1991-09-10
HU193227B (en) 1987-08-28
IT8422744A0 (it) 1984-09-20
GB8423863D0 (en) 1984-10-24
CS249147B2 (en) 1987-03-12
AT387965B (de) 1989-04-10
IT1176739B (it) 1987-08-18
ZA847345B (en) 1985-06-26
SE8404729L (sv) 1985-03-22
ES8704465A1 (es) 1987-04-01
GB2146994A (en) 1985-05-01
NO843726L (no) 1985-03-22
DK162987B (da) 1992-01-06
ES8702897A1 (es) 1987-01-16
IE58083B1 (en) 1993-06-30
AR242789A1 (es) 1993-05-31
HUT35259A (en) 1985-06-28
HK73790A (en) 1990-09-28
PT79256A (en) 1984-10-01
LU85550A1 (fr) 1985-06-04

Similar Documents

Publication Publication Date Title
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
TNSN92109A1 (fr) Nouveaux derives de peptide
FR2356424A1 (fr) Compositions pharmaceutiques a base d'acide phophono-formique utiles pour lutter contre les infections virales
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
NO810478L (no) Fremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazolderivater
TNSN04212A1 (fr) Sels de tolterodine
IE813104L (en) Method and compounds for treating inflammatory bowel¹disease
GB1380129A (en) Benzofuran derivatives and preparation thereof
NO824062L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
FR2438654A1 (fr) Compose de 2-methyl-dihydropyridine, procedes pour son obtention et composition pharmaceutique contenant ce compose
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
ES8605507A1 (es) Un compuesto de 3-indolcarboxamida
RU95109159A (ru) Новые биологически активные композиции, их получение и применение
US4389415A (en) Method of treating hypertension
EP0201094A3 (fr) Dérivés de thiéno[2,3-d] imidazole et leur procédé de préparation
BE900652A (fr) 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2, et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs.
FR2420344A1 (fr) Nouveaux oxime-ethers, leur preparation et leur application therapeutique.
KR940010999A (ko) 이미다졸-1-일 화합물을 포함하는 새로운 약제
ES8308833A1 (es) "un metodo para la preparacion de 3-fenil-1-indanaminas".
US4163054A (en) Anti-hypertensive compositions
HU199290B (en) Process for production of medical compositions against hyperurichemie containing derivatives of oxoquinasoline
US4720379A (en) Use of dimercaptopropanesulfonic acid and dimercapto-propanesuccinic acid for the preparation of pharmaceutical compositions and a method of treatment
FR2421173A1 (fr) 2-(4-ethylpiperazino)-4-phenylquinoleine et ses sels, utiles notamment comme antidepresseurs, et leur procede de preparation
FR2369216A1 (fr) Produits pour le traitement d'eaux, contenant des acides acylimino diacetiques

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: BRISTOL-MYERS CY

Effective date: 19950930